Development and validation of a UPLC-MS method for determination of atazanavir sulfate by the "analytical quality by design" approach.
Abstract
A UPLC-MS method for the estimation of atazanavir sulfate was developed using the "analytical quality by design" approach. The critical chromatographic quality attributes identified were retention time, theoretical plates and peak tailing. The critical method parameters established were percent of organic modifier, flow rate and injection volume. Optimization performed using Box-Behnken Design (BBD) established 10 % organic modifier, 0.4 mL min-1 flow rate and 6-µL injection volume as the optimum method conditions. Atazanavir sulfate eluted at 5.19 min without any interference. Method validation ...
Source: Acta Pharmaceutica - November 6, 2019 Category: Drugs & Pharmacology Authors: Saha C, Gupta NV, Chandan RS Tags: Acta Pharm Source Type: research
Long-term oral atazanavir attenuates myocardial infarction-induced cardiac fibrosis.
Abstract
Atazanavir is an antiretroviral medication used to treat and prevent HIV/AIDS, but its effects on cardiac fibrosis are unknown. The aim of this study was to determine the effects of atazanavir on myocardial infarction (MI)-induced cardiac fibrosis in rats and used a TLR 9 antagonist, hydroxychloroquine (HCQ) to elucidate the potential mechanism in vitro. The results indicated that atazanavir significantly attenuated CoCl2-induced neonatal rat cardiac fibroblast (rCFs) proliferation in a concentration-dependent manner. Treatment of rCFs with atazanavir 1-10µM blocked CoCl2-induced nuclear factor k...
Source: European Journal of Pharmacology - March 29, 2018 Category: Drugs & Pharmacology Authors: Zhang G, Zhang X, Li D, Tian J, Jiang W Tags: Eur J Pharmacol Source Type: research
Protective Effect of Atazanavir Sulfate against Pulmonary Fibrosis In Vivo and In Vitro
This article is protected by copyright. All rights reserved. (Source: Basic and Clinical Pharmacology and Toxicology)
Source: Basic and Clinical Pharmacology and Toxicology - June 1, 2017 Category: Drugs & Pharmacology Authors: Shina Song, Yunxia Ji, Guanghua Zhang, Xue Zhang, Bin Li, Defang Li, Wanglin Jiang Tags: Original Article Source Type: research
Atazanavir sulfate + cobicistat for the treatment of HIV infection.
Authors: Antunes F
Abstract
INTRODUCTION: The life expectancy of patients living with HIV has increased significantly in the last two decades, as a result of the great progress in treatment of HIV infection. During this time, several drugs were developed to offer long-term benefits in terms of virologic efficacy, favourable tolerability and toxicity profiles. Pharmacokinetic boosting of protease inhibitors allows a higher genetic barrier, as few or no drug-resistant mutations are detected in patients with virologic failure. Areas covered: Atazanavir sulfate + cobicistat (ATV/c) was recently approved in the...
Source: Expert Review of Anti-Infective Therapy - April 27, 2017 Category: Infectious Diseases Tags: Expert Rev Anti Infect Ther Source Type: research
Development and validation of a stability-indicating RP –HPLC method for estimation of atazanavir sulfate in bulk
Publication date: April 2017 Source:Journal of Pharmaceutical Analysis, Volume 7, Issue 2 Author(s): S. Dey, S. Subhasis Patro, N. Suresh Babu, P.N. Murthy, S.K. Panda A stability-indicating reverse phase–high performance liquid chromatography (RP–HPLC) method was developed and validated for the determination of atazanavir sulfate in tablet dosage forms using C18 column Phenomenix (250mm×4.6mm, 5μm) with a mobile phase consisting of 900mL of HPLC grade methanol and 100mL of water of HPLC grade. The pH was adjusted to 3.55 with acetic acid. The mobile phase was sonicated for 10min and filtered through a 0.45μm...
Source: Journal of Pharmaceutical Analysis - April 11, 2017 Category: Drugs & Pharmacology Source Type: research
Atazanavir
(ATV), also known as Reyataz, is an azapeptide inhibitor of HIV-1 protease. (Source: Aids Info Drugs)
Source: Aids Info Drugs - February 16, 2016 Category: Drugs & Pharmacology Source Type: research
Congenital Anomalies and In Utero Antiretroviral Exposure in Human Immunodeficiency Virus–Exposed Uninfected Infants
Conclusions and RelevanceFew individual ARVs and no drug classes were associated with an increased risk of CAs in HIV-exposed infants after adjustment for calendar year and maternal characteristics. While the overall risk remained low, a relative increase was observed in successive years and with atazanavir exposure. Given the low absolute CA risk, the benefits of recommended ARV therapy use during pregnancy still outweigh such risks, although further studies are warranted. (Source: JAMA Pediatrics)
Source: JAMA Pediatrics - November 10, 2014 Category: Pediatrics Source Type: research
[This Week in Medicine] December 21, 2013–January 3, 2014
Bristol-Myers Squibb has announced that it will share the intellectual property rights to HIV drug atazanavir (Reyataz) to enable generic versions of the drug to be manufactured for use in developing countries. Atazanavir, designed for patients who have become resistant to first-line treatments, is the first such drug in the UN Medicine Patents Pool. (Source: LANCET)
Source: LANCET - December 20, 2013 Category: Journals (General) Authors: The Lancet Tags: This Week in Medicine Source Type: research
